Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

359 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.
Ko JJ, Choueiri TK, Rini BI, Lee JL, Kroeger N, Srinivas S, Harshman LC, Knox JJ, Bjarnason GA, MacKenzie MJ, Wood L, Vaishampayan UN, Agarwal N, Pal SK, Tan MH, Rha SY, Yuasa T, Donskov F, Bamias A, Heng DY. Ko JJ, et al. Among authors: bamias a. Br J Cancer. 2014 Apr 15;110(8):1917-22. doi: 10.1038/bjc.2014.25. Epub 2014 Apr 1. Br J Cancer. 2014. PMID: 24691425 Free PMC article.
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S, Agarwal N, Yu EY, Niegisch G, Necchi A, Sternberg CN, Srinivas S, Alva A, Vaishampayan U, Cerbone L, Liontos M, Rosenberg J, Powles T, Bellmunt J, Galsky MD; RISC Investigators. Bamias A, et al. Ann Oncol. 2018 Feb 1;29(2):361-369. doi: 10.1093/annonc/mdx692. Ann Oncol. 2018. PMID: 29077785 Free PMC article.
Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration.
Bamias A, Tzannis K, Beuselinck B, Oudard S, Escudier B, Diosynopoulos D, Papazisis K, Lang H, Wolter P, de Guillebon E, Stravodimos K, Chrisofos M, Fountzilas G, Elaidi RT, Dimopoulos MA, Bamia C. Bamias A, et al. Br J Cancer. 2013 Jul 23;109(2):332-41. doi: 10.1038/bjc.2013.341. Epub 2013 Jun 27. Br J Cancer. 2013. PMID: 23807171 Free PMC article.
Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.
Elaidi R, Harbaoui A, Beuselinck B, Eymard JC, Bamias A, De Guillebon E, Porta C, Vano Y, Linassier C, Debruyne PR, Gross-Goupil M, Ravaud A, Aitelhaj M, Marret G, Oudard S. Elaidi R, et al. Among authors: bamias a. Ann Oncol. 2015 Feb;26(2):378-85. doi: 10.1093/annonc/mdu552. Epub 2014 Dec 1. Ann Oncol. 2015. PMID: 25467013 Free article.
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S, Agarwal N, Yu EY, Niegisch G, Necchi A, Sternberg CN, Srinivas S, Alva A, Vaishampayan U, Cerbone L, Liontos M, Rosenberg J, Powles T, Bellmunt J, Galsky MD; RISC Investigators. Bamias A, et al. Ann Oncol. 2019 Nov 1;30(11):1841. doi: 10.1093/annonc/mdz214. Ann Oncol. 2019. PMID: 31868903 Free PMC article. No abstract available.
359 results